SOPHiA GENETICS SA (SOPH) Eyes $10 Target: +25% Potential Upside Ahead?
Key Takeaways
- The central question is whether SOPHiA GENETICS SA (SOPH) can climb to a $10 stock price target, roughly 25% above recent trading levels.
- Bullish drivers include accelerating revenue growth, raised full-year guidance, expanding U.S. traction, and high-profile companion-diagnostics partnerships.
- The biggest obstacles are persistent net losses, a premium valuation, dilution risk, and insider selling.
- $10 sits just above the stock's 52-week high near $8.98, making it both a psychological milestone and a technical breakout level.
- The level appears achievable over time but likely depends on continued execution and a shift toward profitability.
Understanding SOPHiA GENETICS' Core Business
SOPHiA GENETICS is a Swiss-headquartered, cloud-native healthcare software company that uses artificial intelligence to analyze multimodal data, including genomics and clinical information, to support oncology and rare-disease diagnostics. Its core offering, the SOPHiA DDM platform, is used by hundreds of hospitals, laboratories, and biopharmaceutical companies worldwide. The company generates recurring, usage-based revenue each time its platform analyzes a sample, giving the business a software-like model with a reported gross margin in the high-60% range. From what I see, this recurring element stands out as a key strength in the diagnostics space.
Current Market Position and Recent Performance
Shares trade near $8, well above their 52-week low of about $3.15 and just under their 52-week high near $8.98. The stock has climbed significantly over the past year, supported by strong quarterly results. In its most recent quarter, the company reported roughly 27% year-over-year revenue growth, including 60% volume growth in the United States and 80% revenue growth in its liquid-biopsy segment. Management subsequently raised its full-year revenue outlook to a range of $94 million to $96 million, above prior consensus expectations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Why the $10 Level Carries Weight
A $10 price target matters for two reasons. First, it is a round, psychological number that investors tend to track closely. Second, it aligns closely with Wall Street's consensus analyst price target, which currently sits near $9.75 to $10. Because the stock has not yet traded above $10, the level represents both a fresh round-number milestone and a breakout above its prior 52-week high. That combination makes $10 the most widely watched objective in current market discussion.
Factors That Could Support a Move Higher
Several factors support a path toward $10. The company's companion-diagnostics work, including partnerships linked to AstraZeneca, expands its presence in precision oncology. A joint venture with a major cancer center and growing adoption of its platform across U.S. health systems point to a larger installed base. Analysts at H.C. Wainwright have pointed to an estimated $40 billion addressable market and a recurring, usage-based revenue model as key differentiators. Continued revenue growth above 20%, improving margins, and a shrinking adjusted EBITDA loss would strengthen the bull case.
Key Risks That Could Hold the Stock Back
The primary obstacle is profitability. SOPHiA GENETICS remains deeply unprofitable, with a negative net margin and negative earnings per share (EPS), a measure of profit allocated to each share. The company has funded itself partly through equity offerings, which dilute existing shareholders, and insiders have sold shares under pre-arranged plans. The stock also carries a premium valuation, with analysts' models implying a forward price-to-earnings (P/E) ratio near 97 times, which leaves little room for execution missteps. Any slowdown in adoption, weaker-than-expected growth, or further dilution could delay a move toward $10.
Analyst Views and Price Targets
Sell-side views are constructive but wide-ranging. The consensus rating is generally described as a Strong Buy, with an average analyst price target near $9.75 to $10. Individual targets vary sharply, from $7 at the low end to $14 at the high end. BTIG has raised its target to $9, while H.C. Wainwright has lifted its target to $14. The spread reflects genuine disagreement about how quickly the company can scale toward profitability, meaning $10 sits squarely in the middle of the analyst range rather than at its extremes.
Important Technical Levels to Watch
From a technical analysis perspective, the $8.98 area, the prior 52-week high, is the first important resistance level. A decisive close above that zone would clear the way toward the $10 round-number objective. On the downside, support appears near the $7 area, with longer-term support reflected by the 200-day moving average around $5.71. The stock's longer-term trend structure has turned upward, but $10 will not be reached without first converting the prior high from resistance into support.
Final Assessment
A move to $10 appears realistic but not guaranteed. The company's accelerating growth, raised guidance, and expanding partnerships provide a credible foundation, and $10 aligns closely with the analyst consensus. However, persistent losses, a high valuation, and dilution risk are meaningful headwinds. Investors should monitor revenue growth rates, progress toward profitability, the sustainability of U.S. adoption, and whether shares can hold above the $8.98 prior high. Without sustained execution, the $10 level may remain just out of reach; with it, the target becomes a plausible near-to-medium-term objective.
Using AI Tools in My Research Process
One tool I find useful for tracking momentum in names like this is Tickeron's AI Daily Buy/Sell Signals. It applies artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. This helps me spot shifts in trend more efficiently when evaluating whether a stock can sustain a move toward key levels like $10.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SOPH's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for SOPH moved out of overbought territory on August 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 18 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SOPH as a result. In 98 of 118 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for SOPH turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 45 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 72 cases where SOPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOPH advanced for three days, in 202 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
SOPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 111 of 129 cases where SOPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SOPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.150) is normal, around the industry mean (7.455). SOPH has a moderately low P/E Ratio (0.000) as compared to the industry average of (45.054). SOPH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.518). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (6.443) is also within normal values, averaging (6.089).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement